Biotech Stocks: The Sector's Most Comprehensive Immunotherapy Platforms

The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research. While the larger research entities like NCI get all the press coverage and media attention, it's the smaller highly specialized organizations working behind the scenes that are the real heroes.

In biotech's immunotherapy sector alone there are emerging names like Galena Biopharma (NASDAQ:GALE) with a Market Cap of $242M trading at $2.05/share, Lion Biotechnologies Inc (OTCMKTS:LBIO) Trading at $6.39/share with a $175M Market Cap, Inovio Pharmaceuticals (NASDAQ:INO) with a market cap of $686.13M and a share price of $11.36/share, Northwest Biotherapeutics (NASDAQ:NWBO) which trades at $5.26/share and a $324.95M Market Cap and Dendreon Corporation (NASDAQ:DNDN) who finds their individual shares priced at $.97 with a Market Cap if $157.03M.

Some may recall the storied rise of Dendreon which saw shares trade at levels above $50 after their drug PROVENGE(R) received FDA approval as the first autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Like other immunotherapies being developed in this exciting sector, the drug was designed to take the body's own immune cells and reprogram them to attack cancer cells.

While we may never again see the type of euphoria that followed Dendreon, biotech traders and speculators know that finding profitable movers involves solid research and recognizing a combination of  both value and trade catalysts.

One candidate with positive move potential is just starting to find an audience. Seattle basedTapImmune, Inc. (OTCBB:TPIV) is by all appearances making good strides in the prevention and treatment of multiple cancers that feature huge market opportunities.

Trading volume for TapImmune's shares has started to increase in the last month and a half, as the firm's two Phase I Clinical Trials prepare to progress officially to Phase II clinical status (that catalyst is expected to occur sometime soon, during this final quarter of 2014. 

Value drivers gain momentum when pipelines progress, but adding to the anticipatory excitement here is the fact that each of the firm's two lead products feature blockbuster potential. The first presents in the form of a HER2/neu breast cancer vaccine and the second as an urgently needed Ovarian Cancer Therapeutic.

There are several reasons why an entry point trade for TPIV shares looks compelling now, but none is more evident than the low-risk proposition offered at these price levels. Look again, closely, at the market caps and share prices for some of the immunotherapy developers mentioned above consider that TapImmune shares can be had for a mere $.38 per share. Yes, TPIV is currently priced like an option that won't expire despite the fact that shares traded as high as $7 quite recently. The firm's market cap has been inexplicably punished to a valuation under $8M following a recent corporate re-structure designed to eliminate debt and allow for recent capital raise financings.

1 2 3 4
View single page >> |

Disclosure: This article contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.